drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered with a murine-derived anti-CD19 chimeric antigen receptor to target CD19 on B-ALL blasts, triggering CD3ΞΆ-mediated activation, cytokine release, and cytotoxic killing; induces B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a murine-derived anti-CD19 chimeric antigen receptor bind CD19 on B-cell leukemia cells. CAR engagement triggers CD3zeta-mediated signaling (with costimulation), activating T cells to proliferate, release cytokines, and exert cytotoxic killing, leading to depletion of CD19+ B cells (B-cell aplasia).
drug_name
CD19 CAR T cells
nct_id_drug_ref
NCT06343090